The essentials
- There is no approved dose of retatrutide. The only human dosing data comes from clinical trials, which used 0.5–12 mg once weekly with escalation steps of at least four weeks. No human data exists above 12 mg per week.
- Side effects in the trials were dose-related — mostly gastrointestinal, with dose-dependent heart-rate increases — and were reduced by starting low and escalating slowly.
- Retatrutide’s half-life is around six days, so weekly doses accumulate for roughly a month. Increasing a dose before the previous level has plateaued is how people end up far above where they think they are.
- Severe abdominal pain, repeated vomiting, right-upper-quadrant pain, or a racing heartbeat are medical red flags, not side effects to wait out — seek medical care and tell the clinician what was taken.
- RETApro supplies retatrutide strictly for laboratory research. This centre is educational harm-reduction information drawn from published trials, not medical advice and not instructions for use.
The safety guides
Dosing: what the trials actually did
There is no approved human dose of retatrutide. This guide sets out the only real human dosing data that exists — the clinical-trial titration schedules — plus the half-life maths that makes dose stacking dangerous, and the reconstitution errors behind most accidental overdoses.
Side effects, including at higher doses
The adverse events reported in the Phase 2 and Phase 3 programmes, how they scaled with dose, the class-effect risks (pancreatitis, gallbladder disease, hypoglycaemia in combination), and why nothing is known above 12 mg per week.
Red flags: when to seek medical help
The trial programmes logged a small number of serious adverse events alongside the common gastrointestinal ones. Outside a trial there is no investigator watching, so these symptoms should be treated as reasons to seek urgent medical care — not discomfort to push through:
- Severe, persistent abdominal pain — especially pain radiating through to the back (possible pancreatitis)
- Repeated vomiting or an inability to keep fluids down for more than a day (dehydration and acute kidney injury risk)
- Pain under the right ribs, fever, or yellowing of the skin or eyes (possible gallbladder disease)
- A racing or irregular heartbeat at rest, chest pain, or fainting
- Symptoms of low blood sugar — shaking, sweating, confusion — particularly alongside insulin or sulfonylureas
- Swelling of the face or throat, difficulty breathing, or widespread rash (allergic reaction)
- A lump in the neck, persistent hoarseness, or difficulty swallowing
Regulatory labels across the GLP-1 class also warn against use in pregnancy or breastfeeding, with a personal or family history of medullary thyroid carcinoma or MEN 2, or with a history of pancreatitis. Retatrutide has no label of its own — which means those exclusions were enforced by trial screening, not waived.
Handling, storage, and sourcing
Cold chain and storage
Retatrutide belongs at 2–8 °C, protected from light, in every format. For lyophilised vials, the clock starts at reconstitution: solutions made with plain sterile water have no preservative and are single-session material, while bacteriostatic preparations are typically treated as usable for up to about 28 days refrigerated. Pre-mixed pens — the format RETApro supplies — are in solution for their whole life, so they are refrigerated from delivery onward and carry the same in-use window from first use; they should never be frozen. In any format, cloudiness, particles, or colour change mean discard.
Counterfeit and mislabelled material
Independent testing of grey-market GLP-1-class vials has repeatedly found underdosed, overdosed, and entirely different compounds. A vial whose true content is unknown makes every safety consideration on this page unreliable. Insist on a batch-matched, independently verifiable Certificate of Analysis, and treat unusually cheap material as a warning sign, not a bargain.
Tell the clinicians who treat you
GLP-1-class compounds slow gastric emptying. Anaesthetists specifically ask about them before surgery because of aspiration risk, and a GP cannot interpret nausea, gallbladder symptoms, or blood-sugar changes without knowing what is on board. If retatrutide is being used outside a trial, the single most protective thing a person can do is make sure their doctor knows. In the UK, suspected adverse reactions — including to unlicensed products — can be reported through the MHRA Yellow Card scheme.
Frequently asked questions
Is there an official dosing guideline for retatrutide?
No. Retatrutide is investigational and has no approved dose, no prescribing information, and no licensed indication anywhere in the world. The only human dosing data that exists comes from clinical trials, which used once-weekly subcutaneous doses between 0.5 mg and 12 mg with slow escalation steps of at least four weeks. Anything beyond that — higher doses, faster escalation, combining compounds — has never been tested in humans.
What happens at doses above 12 mg per week?
Nobody knows — 12 mg once weekly is the highest dose ever studied in humans. Within the trials, side effects were clearly dose-related, so the reasonable expectation is that risk continues to rise above the studied range while any additional benefit is completely unquantified. With a half-life of roughly six days, weekly doses also accumulate for about a month before levels plateau, so the full effect of a dose increase is not felt for several weeks.
What are the most common side effects seen in the trials?
Gastrointestinal effects — nausea, diarrhoea, vomiting, and constipation — were the most frequently reported adverse events. They were dose-related, mostly mild to moderate, and less frequent when treatment started at a lower dose and escalated slowly. Dose-dependent increases in resting heart rate and reports of altered skin sensation were also observed. Serious class-associated risks include pancreatitis and gallbladder disease.
Why does a research-chemical supplier publish safety information?
Because accurate information reduces harm and inaccurate information causes it. Retatrutide is sold here strictly for laboratory research, but the compound is widely discussed online and much of what circulates about dosing is folklore. Publishing what the peer-reviewed literature actually reports — including the risks — is the responsible alternative to leaving that vacuum to forums. Nothing in this centre is medical advice or an instruction for human use.